Now on home page

ADS

Research progress on the chemical components and pharmacological effects of Physalis alkekengi L. var. franchetii (Mast.) Makino

Abstract

Physalis Calyx seu Fructus is the dry calyx or the calyx with fruit of the Solanaceae plant Physalis alkekengi L. var. franchetii (Mast.) Makino, with a long history of use in medicine and food. However, despite its many potential therapeutic and culinary applications, P. alkekengi is not being exploited for these applications on a large scale. This study analysed various research related to the different chemical components of P. alkekengi, including steroids, flavonoids, alkaloids, phenylpropanoids, sucrose esters, piperazines, volatile oils, polysaccharides, amino acids, and trace elements. In addition, research related to the pharmacological activities of P. alkekengi, including its anti-inflammatory, anti microbial, antioxidative, hypoglycaemic, analgesic, anti-tumour, and immunomodulatory effects were investigated. Research articles from 1974 to 2023 were obtained from websites such as Google Scholar, Baidu Scholar, and China National Knowledge Infrastructure, and journal databases such as Scopus and PubMed, with the keywords such as Physalis alkekengi, components, effects, and activities. This study aims to provide a comprehensive understanding of the progress of phytochemical and pharmacological research on the phytochemical and pharmacological aspects of P. alkekengi and a reference for the better exploitation of P. alkekengi in the food and pharmaceutical industries.


Publication:
Heliyon
Pub Date:
December 2023
DOI:

10.1016/j.heliyon.2023.e20030

Bibcode:
2023Heliy...920030L
Keywords:
  • Physalis alkekengi;
  • Chemical components;
  • Pharmacological effects;
  • Mechanisms;
  • Physalins;
  • Botanical origin;
  • SOD;
  • Superoxide dismutase;
  • CAT;
  • Catalase;
  • GSH-Px;
  • Glutathione peroxidase;
  • COX-2;
  • Cyclooxygenase;
  • 5-LOX;
  • 5-Lipoxygenase;
  • PLA2;
  • Phospholipase A2;
  • PGE2;
  • Prostaglandin E2;
  • LTB4;
  • Leukotriene B4;
  • IL;
  • Interleukin;
  • LPS;
  • Lipopolysaccharide;
  • Akt;
  • also known as;
  • PKB;
  • Protein kinase B;
  • MAPK;
  • Mitogen-activated protein kinase;
  • NF-κB;
  • Nuclear factor kappa-B;
  • iNOS;
  • Inducible nitric oxide synthase;
  • NO;
  • Nitric oxide;
  • TNF-α;
  • Tumor necrosis factor-α;
  • MCP-1;
  • Monocyte chemotactic protein-1;
  • IκB-α;
  • Inhibitor of NF-κB;
  • NAFLD;
  • Nonalcoholic fatty liver disease;
  • MDA;
  • Malondialdehyde;
  • DPPH;
  • 2;
  • 2-Diphenyl-1-picrylhydrazyl;
  • OH;
  • Hydroxyl radical;
  • ABTS;
  • 2;
  • 2-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid);
  • O2-;
  • Superoxide anion;
  • NaNO2;
  • Sodium nitrite;
  • KEAP1;
  • Kelch-like ECH-associated protein 1;
  • NRF2;
  • Nuclear factor-erythroid 2-related factor 2;
  • STZ;
  • Streptozotocin;
  • GLUT4;
  • Glucose transporter 4;
  • PI3K;
  • Phosphatidylinositol-3-kinase;
  • InsR;
  • Insulin receptor;
  • GK;
  • Glucokinase;
  • GLUT2;
  • Glucose transporter 2;
  • PK;
  • Pyruvate kinase;
  • PEPCK;
  • Phosphoenolpyruvate carboxykinase;
  • LTA4H;
  • Leukotriene A-4 hydrolase;
  • IgG;
  • Immunoglobulin G;
  • IgG1;
  • Immunoglobulin G1;
  • IgG2b;
  • Immunoglobulin G2b;
  • STAT3;
  • Signal transducers and activators of transcription 3;
  • ROS;
  • Reactive oxygen species;
  • JAK2;
  • Janus kinase 2;
  • CDK1;
  • Cycle protein-dependent kinase 1;
  • PARP;
  • Poly ADP-ribose polymerase;
  • mTOR;
  • Mammalian target of rapamycin;
  • CDK2;
  • Cyclin-dependent kinase 2;
  • MET;
  • Mesenchymal-epithelial transition protein;
  • OVA;
  • Ovalbumin;
  • IFN-γ;
  • Interferon γ;
  • PKC;
  • Protein kinase C
full text sources
Publisher
|